CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc. presented data that sets a new standard for EGFR-T790M resistance mutation detection in lung cancer, with the highest sensitivity reported ...
A blood-based liquid biopsy test detects early-onset colorectal cancer with strong diagnostic performance and high ...
Exosome Diagnostics recently announced the launch of ExoDx Lung(ALK), a liquid biopsy platform that allows for non-invasive detection of biomarkers and potentially negates the need for a tissue biopsy ...
Earlier this year, Exosome Diagnostics said that it would scout out deals with biopharma partners to gain ground with its liquid biopsy tests. Now, the company is ...
Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore), or EPI, through FedMed, Inc., a ...
Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback